Paper Details

  1. Home
  2. Paper Details

[Prophylactic systemic antibiotherapy with only ceftriaxone in neutropenic patients treated in a protected environment].

Author: BourhisJ H, CourtieuA L, DerriennicM, HarousseauJ L, MilpiedN, ReynaudA E

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
English AbstractA summary of a research paper/publication written in English for a wider audience.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Prophylactic systemic antibiotherapy with ceftriaxone (CRO) was effective in reducing the risk of bacterial infections in aplastic patients receiving total gut decontamination and treated in a protected environment. The use of CRO significantly reduced the incidence of fever and bacteremia, with no deaths recorded during the study.
Paper Details　
Original Abstract of the Article :
Prophylactic systemic antibiotherapy with ceftriaxone (CRO) alone was tested in aplastic patients receiving total gut decontamination and treated in protected environment. To enter the study, the patients had to be afebrile when their polymorphonuclear (PMN) count fell under 500/cumm. Seventy eight ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/3059275

データ提供：米国国立医学図書館（NLM）

Prophylactic Systemic Antibiotherapy with Only Ceftriaxone in Neutropenic Patients Treated in a Protected Environment

This study delves into the efficacy of a single-antibiotic prophylactic approach, specifically ceftriaxone, in neutropenic patients undergoing treatment in a protected environment. The researchers meticulously evaluated the outcomes of this approach in a group of patients undergoing bone marrow transplantation or high-dose chemotherapy, comparing it to a control group receiving no prophylactic antibiotics.

The study demonstrates that prophylactic ceftriaxone significantly reduced the incidence of bacterial infections and fevers in neutropenic patients treated in a protected environment. This finding offers a valuable alternative to multi-antibiotic prophylactic regimens, minimizing side effects and costs. This research is like a desert explorer meticulously navigating a treacherous landscape, seeking the most effective and safe path to success.

A New Approach to Infection Prevention in Neutropenic Patients

This study offers a promising new approach to infection prevention in neutropenic patients, minimizing the use of antibiotics and potentially reducing the risk of antibiotic resistance. It's like a camel using its powerful legs to navigate through a challenging desert, finding a new and efficient way to reach its destination.

Protecting Vulnerable Patients: A Minimally Invasive Approach

This study provides a valuable alternative to traditional multi-antibiotic prophylactic regimens for neutropenic patients, emphasizing the importance of a targeted and minimally invasive approach to infection prevention. It's like a camel using its ability to store water for long journeys, finding a sustainable and efficient way to protect its health.

Dr.Camel's Conclusion

This study highlights the potential benefits of a single-antibiotic prophylactic approach for neutropenic patients treated in a protected environment. It offers a promising new strategy for reducing the risk of infections while minimizing side effects and costs.

Date :
  1. Date Completed 1989-01-24
  2. Date Revised 2013-11-21
Further Info :

Pubmed ID

3059275

DOI: Digital Object Identifier

3059275

Related Literature

Article Analysis
・Side Effects of cefotaxime injection
SNS
PICO Info
in preparation
Languages

French

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.